OKYO (OKYO Pharma) Institutional Ownership : 2.96% (As of Dec. 12, 2024)

View and export this data going back to 2022. Start your Free Trial

What is OKYO Pharma Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, OKYO Pharma's institutional ownership is 2.96%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, OKYO Pharma's Insider Ownership is 54.38%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, OKYO Pharma's Float Percentage Of Total Shares Outstanding is 72.38%.

OKYO Pharma Institutional Ownership Historical Data

The historical data trend for OKYO Pharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OKYO Pharma Institutional Ownership Chart

OKYO Pharma Historical Data

The historical data trend for OKYO Pharma can be seen below:

	2024-02-29	2024-03-31	2024-04-30	2024-05-31	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30
Institutional Ownership	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04

OKYO Pharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

OKYO Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OKYO Pharma Ltd (NAS:OKYO) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

14/15 Conduit Street, Floor 4, London, GBR, W1S 2XJ

Website

https://www.okyopharma.com

OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.

Executives

John P Brancaccio	director	C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Gary S Jacob	director, officer: Chief Executive Officer
Gabriele M Cerrone	director, 10 percent owner, officer: Executive Chairman	265 EAST 66TH STREET, SUITE 16G, NEW YORK NY 10021
Bernard Denoyer	director	C/O CALLISTO PHARMACEUTICALS, INC., 420 LEXINGTON AVENUE, SUITE 1609, NEW YORK NY 10170
Willy Jules Simon	director	PLAYLOGIC INTERNATIONAL NV, CONCERTGEBOUWPLEIN 13, AMSTERDAM P7 1071 LL
Keeren Shah	officer: Chief Financial Officer	55 PARK LANE, LONDON X0 W1K 1NA